Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about

< Previous 1 2 Next >
40 Biggest Movers From Yesterday
Gainers AGM Group Holdings Inc. (NASDAQ: AGMH) shares jumped 71.39 percent to close at $27.80 on Thursday. Destination Maternity ... 
Tags BMA CYTX ACHV
From Benzinga
Benzinga's Weekly Movers For The Week Of May 25, 2018
Benzinga’s Weekly Movers For The Week Of May 25, 2018 The data presented below was compiled using a Screener widget and ... 
Tags CYTX REPH ACHV
From Benzinga
BRIEF-Cytori Therapeutics - Co Met With U.S. FDA To Discuss Outcome Of Star Clinical Trial
* CYTORI THERAPEUTICS - ON MARCH 1, CO MET WITH U.S. FDA TO DISCUSS OUTCOME OF STAR CLINICAL TRIAL AND CO'S PLANS FOR HABEO CELL THERAPY - SEC FILING 
Tags companyNews
From Reuters: Company News
Cytori Therapeutics Q4 Earnings Preview
On Thursday, Cytori Therapeutics (NASDAQ: CYTX) will release its latest earnings report. Here is Benzinga's outlook for the ... 
Tags Earnings Previews News Earnings
From Benzinga
BRIEF-Cytori Therapeutics Says David Rickey And Gail Naughton Submitted Resignations As Members Of Board
* CYTORI THERAPEUTICS - ON JAN 25, AS PART OF ONGOING RESTRUCTURING DAVID M. RICKEY AND GAIL K. NAUGHTON, SUBMITTED RESIGNATIONS AS MEMBERS OF BOARD 
Tags companyNews
From Reuters: Company News
BRIEF-Swissquote Bank Sells 188,426 Shares Of Cytori Therapeutics Inc's Common Stock Between Jan 9-11
* SWISSQUOTE BANK SA REPORTS OPEN MARKET SALE OF 188,426 SHARES OF CYTORI THERAPEUTICS INC'S COMMON STOCK BETWEEN JAN 9 AND JAN 11 - SEC FILING Source text: (http://bit.ly/2ExdrAg) Further company... 
Tags companyNews
From Reuters: Company News
BRIEF-Swissquote Bank SA Reports 12 pct Passive Stake In Cytori Therapeutics As Of Dec. 29, 2017
* SWISSQUOTE BANK SA REPORTS 12 PERCENT PASSIVE STAKE IN CYTORI THERAPEUTICS INC AS OF DECEMBER 29, 2017 - SEC FILING?? Source text - (http://bit.ly/2CUutMr) Further company coverage: 
Tags companyNews
From Reuters: Company News
BRIEF-Cytori Therapeutics enters into an amendment to its existing loan and security agreement
* Cytori Therapeutics- On September 20, 2017, co entered into an amendment to its existing loan and security agreement, dated May 29, 2015 - SEC filing 
Tags companyNews
From Reuters: Company News
BRIEF-Cytori announces corporate restructuring & cost reduction plan
* Cytori announces corporate restructuring & cost reduction plan 
Tags companyNews
From Reuters: Company News
20 Biggest Mid-Day Losers For Tuesday
Neuralstem, Inc. (NYSE: CUR) shares dipped 59.1 percent to $2.29 after the company disclosed that top-line Phase 2 for NSI-189 ... 
Tags JAKK STX Intraday Update
From Benzinga
Benzinga's Top Upgrades, Downgrades For July 25, 2017
Top Upgrades Bank of America upgraded Werner Enterprises, Inc (NASDAQ: WERN) from Underperform to Neutral. Werner shares ... 
Tags Apparel, Accessories & Luxury Goods BY DSW
From Benzinga
The Market In 5 Minutes
IN THE NEWS Benzinga Blue Apron Holdings Inc (NYSE: APRN) shares jumped 13 percent on Monday after a number of its IPO underwriters ... 
Tags CYTX MDLZ LULU
From Benzinga
BRIEF-Cytori announces top-line 24- and 48-week results
* Cytori announces top-line 24- and 48-week results from the star trial of habeo cell therapy in patients with scleroderma 
Tags companyNews
From Reuters: Company News
BRIEF-Cytori Therapeutics receives key cell therapy patent for scleroderma
* Cytori Therapeutics - receives key cell therapy patent for scleroderma, patent has a term at least through 2034 Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
BRIEF-Cytori Therapeutics announces publication of long-term follow-up data for cancer recurrences following use of Cytori cell therapy
* Cytori Therapeutics announces publication of long-term follow-up data for cancer recurrences following use of Cytori cell therapy 
Tags companyNews
From Reuters: Company News
Premarket Biotech Digest – AVGR Announces Positive Data, CXRX To Be Investigated
Microbot Medical Inc. (MBOT) announced receiving a new patent from the Canadian Intellectual Property Office. Avinger (AVGR) stock soared as the company announced the positive 24 month data from the... 
Tags Healthcare Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
BRIEF-Cytori and Barda execute $13.4 mln contract option for burn clinical trial
* Cytori and Barda execute $13.4 million contract option for burn clinical trial 
Tags companyNews
From Reuters: Company News
BRIEF-Cytori and Barda execute $13.4 mln contract option for burn clinical trial
* Cytori and Barda execute $13.4 million contract option for burn clinical trial 
Tags companyNews
From Reuters: Company News
BRIEF-Cytori Therapeutics completes follow up monitoring visits in FDA approved late-stage STAR trial
* Cytori Therapeutics Inc - now completed all 48 week follow up monitoring visits in its U.S. FDA approved phase III star trial Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
22 Stocks Moving In Friday's Pre-Market Session
Gainers GlycoMimetics Inc (NASDAQ: GLYC) shares rose 10.6 percent to $11.80 in pre-market trading after climbing 98.70 ... 
Tags LL CYTX CPB
From Benzinga
25 Stocks Moving In Thursday's Pre-Market Session
Gainers GlycoMimetics Inc (NASDAQ: GLYC) shares rose 35 percent to $7.25 in pre-market trading as the company reported that ... 
Tags BBD P RL
From Benzinga
BRIEF-Cytori Therapeutics files for mixed shelf of up to $100 mln
* Files for mixed shelf of up to $100.0 million - SEC filing Source text (http://bit.ly/2pGYfZe) Further company coverage: 
Tags companyNews
From Reuters: Company News
BRIEF-Cytori Q1 adjusted loss per share $0.26 excluding items
* Cytori reports first quarter 2017 business and financial results 
Tags companyNews
From Reuters: Company News
BRIEF-Cytori Therapeutics announces follow up data of ADRCs treatment in post prostatectomy erectile dysfunction
* Cytori Therapeutics Inc - one year follow up data of adrcs (cytori cell therapy) treatment in post prostatectomy erectile dysfunction 
Tags companyNews
From Reuters: Company News
Cytori Therapeutics prices offering at discount
Cytori Therapeutics Inc. (Nasdaq: CYTX) priced its public offering of 8.6 million common shares at the discounted price of $1.10 per share sending the stock price down 60 cents to close at $1.12.... 
From MarketMinute.com Stock News
11 Biggest Mid-Day Losers For Tuesday
Avinger Inc (NASDAQ: AVGR) shares plummeted 51.56 percent to $0.77, after having soared on April 10. Cytori Therapeutics ... 
Tags Markets NAKD Mid/Day Losers
From Benzinga
Lower open as Secretary of State arrives in Moscow
The markets opened lower with the Dow falling 55 points to 20,602 as Secretary of State Rex Tillerson arrived in Moscow to discuss the Syrian conflict. Nasdaq dropped 35 points to 5,845. 
Tags Market News
From MarketMinute.com Market Updates
BRIEF-Cytori says public offering of 8.60 mln common shares priced at $1.10 per share
* Cytori announces pricing of $9.5m public offering of common stock 
Tags companyNews
From Reuters: Company News
Cytori Announces Proposed Public Offering Of Common Stock
Cytori Therapeutics, Inc. announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering are to be sold by... 
Tags Healthcare Stocks / Equities
From Blogs - TalkMarkets
FDA approves Cytori Therapeutics' exemption
The Food and Drug Administration approved Cytori Therapeutics Inc.'s (Nasdaq: CYTX) Investigational Device Exemption for a pilot clinical trial to evaluate Cytori Cell Therapy in patients with thermal... 
From MarketMinute.com Stock News
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.